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Diabetes Reduces Mesenchymal Stem Cells in Fracture Healing Through a TNFα-
Mediated Mechanism 
Abstract 
Aims/hypothesis 
Diabetes interferes with bone formation and impairs fracture healing, an important complication in 
humans and animal models. The aim of this study was to examine the impact of diabetes on 
mesenchymal stem cells (MSCs) during fracture repair. 
Methods 
Fracture of the long bones was induced in a streptozotocin-induced type 1 diabetic mouse model with or 
without insulin or a specific TNFα inhibitor, pegsunercept. MSCs were detected with cluster 
designation-271 (also known as p75 neurotrophin receptor) or stem cell antigen-1 (Sca-1) antibodies in 
areas of new endochondral bone formation in the calluses. MSC apoptosis was measured by TUNEL 
assay and proliferation was measured by Ki67 antibody. In vitro apoptosis and proliferation were 
examined in C3H10T1/2 and human-bone-marrow-derived MSCs following transfection with FOXO1 small 
interfering (si)RNA. 
Results 
Diabetes significantly increased TNFα levels and reduced MSC numbers in new bone area. MSC numbers 
were restored to normal levels with insulin or pegsunercept treatment. Inhibition of TNFα significantly 
reduced MSC loss by increasing MSC proliferation and decreasing MSC apoptosis in diabetic animals, but 
had no effect on MSCs in normoglycaemic animals. In vitro experiments established that TNFα alone was 
sufficient to induce apoptosis and inhibit proliferation of MSCs. Furthermore, silencing forkhead box 
protein O1 (FOXO1) prevented TNFα-induced MSC apoptosis and reduced proliferation by regulating 
apoptotic and cell cycle genes. 
Conclusions/interpretation 
Diabetes-enhanced TNFα significantly reduced MSC numbers in new bone areas during fracture healing. 
Mechanistically, diabetes-enhanced TNFα reduced MSC proliferation and increased MSC apoptosis. 
Reducing the activity of TNFα in vivo may help to preserve endogenous MSCs and maximise regenerative 
potential in diabetic patients. 
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Abstract
Aims/hypothesis—Diabetes interferes with bone formation and impairs fracture healing, an 
important complication in humans and animal models. The aim of this study was to examine the 
impact of diabetes on mesenchymal stem cells (MSCs) during fracture repair.
Methods—Fracture of the long bones was induced in a streptozotocin-induced type 1 diabetic 
mouse model with or without insulin or a specific TNFα inhibitor, pegsunercept. MSCs were 
detected with cluster designation-271 (also known as p75 neurotrophin receptor) or stem cell 
antigen-1 (Sca-1) antibodies in areas of new endochondral bone formation in the calluses. MSC 
apoptosis was measured by TUNEL assay and proliferation was measured by Ki67 antibody. In 
vitro apoptosis and proliferation were examined in C3H10T1/2 and human-bone-marrow-derived 
MSCs following transfection with FOXO1 small interfering (si)RNA.
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Results—Diabetes significantly increased TNFα levels and reduced MSC numbers in new bone 
area. MSC numbers were restored to normal levels with insulin or pegsunercept treatment. 
Inhibition of TNFα significantly reduced MSC loss by increasing MSC proliferation and 
decreasing MSC apoptosis in diabetic animals, but had no effect on MSCs in normoglycaemic 
animals. In vitro experiments established that TNFα alone was sufficient to induce apoptosis and 
inhibit proliferation of MSCs. Furthermore, silencing forkhead box protein O1 (FOXO1) 
prevented TNFα-induced MSC apoptosis and reduced proliferation by regulating apoptotic and 
cell cycle genes.
Conclusions/interpretation—Diabetes-enhanced TNFα significantly reduced MSC numbers 
in new bone areas during fracture healing. Mechanistically, diabetes-enhanced TNFα reduced 
MSC proliferation and increased MSC apoptosis. Reducing the activity of TNFα in vivo may help 
to preserve endogenous MSCs and maximise regenerative potential in diabetic patients.
Keywords
Anti-TNF; Cytokine; Diabetes; Forkhead; Fracture healing; Hyperglycaemia; Inflammation; 
Mesenchymal stem cell; Tumour necrosis factor
Introduction
Diabetes mellitus is one of the most common metabolic diseases, with 439 million people 
estimated to be affected worldwide by 2030 [1]. Diabetic patients have a greater risk of 
fracture and an increased risk of delayed union and non-union fracture healing [2-4]. 
Though the aetiology of diabetic complications is multifactorial, chronic inflammation is 
thought to play a critical role in several diabetic complications [5, 6]. It has been implicated 
in diabetic osteopaenia and reduced bone formation associated with impaired fracture repair 
in humans and in animal models of diabetes [7-9].
Fracture healing is a regenerative process that involves the coordinated activity of 
inflammatory cells, endothelial cells, stem cells, chondrocytes, osteoblasts and other cell 
types [10]. In an experimental animal model of fracture healing, mice with streptozotocin 
(STZ)-induced diabetes exhibited increased inflammation, enhanced osteoclastogenesis, loss 
of cartilage in the callus and reduced bone formation [7, 11, 12].
An inflammatory response is indispensable for proper fracture healing. Mice deficient in 
TNFα receptor or IL-6 show delayed fracture healing [13, 14]. However, animals with 
diabetes or rheumatoid arthritis exhibit elevated TNFα levels and display impaired fracture 
healing [7, 15]. TNFα inhibition increases fracture callus size in mouse models of diabetes 
[16]. Bone-marrow-derived MSCs differentiate to chondrocytes and osteoblasts, which play 
essential roles in endochondral ossification of fracture calluses. MSCs also function as 
trophic mediators that promote angiogenesis, have anti-apoptotic effects and reduce 
inflammation [17]. Therapeutic use of MSCs improves outcomes in the healing response to 
stroke, myocardial infarction and long bone fracture in animal models [18-20], and in the 
treatment of inflammatory diseases in phase 1 and 2 human clinical trials [21, 22]. Although 
MSCs are important in the repair of many different tissues, relatively little is known about 
the impact of diabetes on MSCs in fracture repair. Here, we determined that diabetes affects 
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the number of MSCs in areas of new endochondral ossification in fracture healing in mice. 
Diabetes interferes with MSC proliferation and promotes MSC apoptosis in vivo through a 
mechanism that involves diabetes-enhanced TNFα levels. Thus, in fracture healing, 
diabetes-induced inflammation creates a suboptimal environment for MSC survival and 
ability to proliferate. Given the critical role that MSCs are thought to play in fracture 
healing, this deficit may significantly contribute to the negative effect of diabetes on fracture 
repair.
Methods
Animals
The research was carried out using 8-week-old male CD-1 mice purchased from Charles 
River Laboratories (Wilmington, MA, USA), conforming to a protocol approved by the 
American Association For Laboratory Animal Science (IACUC). The mouse model of type 
1 diabetes induced by STZ has been previously described [11, 16]. Briefly, multiple 
injections of low-dose STZ (40 mg/kg, Sigma-Aldrich, St. Louis, MO, USA) were 
administered to mice daily for 5 days. Mice were considered to be diabetic when blood 
glucose levels exceeded 13.78 mmol/l (250 mg/dl). Mice were diabetic for at least 3 weeks 
prior to starting experiments (see electronic supplementary material [ESM] Table 1 for 
blood glucose levels). A closed–transverse fracture of the mouse tibia or femur was carried 
out as previously described [23, 24]. In one set of experiments, mice were treated with slow-
release insulin as previously described [11]. In another set of experiments, pegsunercept was 
administered by intraperitoneal injection (4 mg/kg, Amgen, Thousand Oaks, CA, USA) 10 
days post-fracture and every 3 days thereafter. The animals were killed by cervical 
dislocation and cardiac puncture under deep sedation with ketamine/xylazine/acepromazine. 
The samples of long bone were collected by carefully trimming the surrounding muscles.
Paraffin sections and histomorphometric analysis—Specimens were fixed, 
decalcified and embedded in paraffin as previously described [11]. Haematoxylin and eosin 
(H&E) staining was performed to determine the centre of the callus, where the callus was 
widest. All histology was performed in sections taken close to the centre of the callus. The 
amount of bone formation was determined by measuring the bone area within the callus in 
tissue sections. Data are presented as mm2 bone per callus and percentage of bone area per 
total callus area. Osteoblasts were identified as cuboidal cells in clusters of three or more 
cells in contact with the bone surface in Toluidine-Blue-stained sections. For each specimen, 
5–10 random fields throughout the areas of new endochondral ossification were examined 
under ×400 magnification.
Immunohistochemistry/fluorescence
Antigen retrieval was induced by pressure heating (>120°C) paraffin slides in 10 mmol/l 
sodium citrate (pH 6.0) using a 2100-Retriever (Aptum, Southampton, UK). A list of 
antibodies and reagents used is provided in ESM Table 2. For immunohistochemistry, the 
primary antibody was localised by incubation with a biotinylated secondary antibody and 
then avidin–horseradish peroxidase. For some analyses, a scale of immunopositive index 
was used as has been previously described [12]: 0 (no immunostaining); 1 (<10% lightly 
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immunostained cells); 2 (<10% moderate-to-darkly immunostained cells); 3 (10-25% 
moderate-to-darkly immunostained cells); 4 (25-40% moderate-to-darkly immunostained 
cells). For immunofluorescence, primary antibody was localised by a biotinylated secondary 
antibody. To enhance the signal, avidin–biotin peroxidase enzyme complex and tyramide 
signal amplification was used. Visualisation was achieved using Alexa 546-conjugated 
streptavidin or fluorescein-conjugated avidin. For double immunofluorescence, residual 
biotin sites and peroxidase activity associated with the first primary antibody were blocked 
with avidin/biotin-blocking reagent and 3% (vol./vol.) hydrogen peroxide. IgG control 
experiments were carried out for each primary antibody, and images were acquired using the 
same exposure time. All histological images were analysed by two independent examiners 
under blinded conditions.
In vitro experiments
In vitro experiments were carried out with a mouse MSC line (C3T10H1/2) and primary 
human bone-marrow-derived MSCs (hBMSCs), which were isolated and characterised as 
previously described [25]. Briefly, isolation of hBMSCs was achieved with plastic 
adherence, and hBMSCs were characterised as CD73+CD90+CD105+CD45− cells that were 
capable of differentiating into osteoblasts and adipocytes. MSCs were grown and maintained 
in α-MEM + 10% (vol./vol.) FBS and 1% (vol./vol.) antibiotic/antimycotic mix. For all in 
vitro experiments, early-passage cells were used as previously determined by population 
doubling [25, 26].
For the apoptosis assay, the cells were allowed to reach 70% confluence and were then 
incubated with TNFα (10 ng/ml) in α-MEM + 0.5% FBS and 1% antibiotic/antimycotic 
mix. Apoptotic cells were labelled with annexin V–biotin or cleaved caspase-3 antibody. 
Five to eight random images were taken per well for the analysis. For the proliferation assay, 
10% FBS medium was used to stimulate proliferation for 12 h. The BrdU Assay Kit (Cell 
Signaling, Danvers, MA, USA) was used according to the manufacturer's protocol. BrdU 
incorporation was quantified by using a 96 well plate reader at λ=450 nm (Infinite M200 
PRO, Tecan, Morrisville, NC, USA).
Transfection experiments were carried out using Lipofectamine 2000 reagent and on-target 
plus smartpool human forkhead box protein O1 small interfering (si)RNA (10 nmol/l) in 
reduced-serum Opti-MEM for 6 h. The extraction of mRNA from each treatment group was 
carried out using an RNAeasy kit (Qiagen, Valencia, CA, USA) according to the 
manufacturer's protocol.
Statistical analysis
All statistical analyses were carried out with a software program (Minitab ver.16, 
www.minitab.com/en-us/). For insulin treatment and in vitro experiments, one-way ANOVA 
was used to determine statistical significance (p<0.05). For pegsunercept-treatment 
experiments and appropriate in vitro experiments, two-way ANOVA followed by Tukey's 
post-hoc test was used to denote significance. All data represent means ± SEM.
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Results
Diabetes decreases CD271+ and Sca-1+ cells during endochondral ossification in healing 
fracture calluses
Active osteogenesis takes place in areas of endochondral bone formation during fracture 
healing, as shown in Fig. 1a. Diabetic mice exhibited a 53% decrease in new bone area in 
healing calluses compared with normoglycaemic mice (p<0.05) (Fig. 1b). When bone area 
was normalised to the total callus area in groups, diabetic mice had 33% less bone formation 
(Fig. 1c). Diabetic mice also had reduced osteoblast numbers (Fig. 1d). We determined 
whether diabetes also led to a reduction in MSC numbers by immunohistochemistry using 
cluster designation-271 (also known as p75 neurotrophin receptor) and stem cell antigen 1 
(Sca-1)-specific antibodies, which are reliable in vivo MSC markers in non-haematopoietic 
connective tissue [27, 28]. The numbers of CD271+ and Sca-1+ cells were significantly 
reduced in diabetic compared with normoglycaemic mice (p<0.05) (Fig. 1e, f). The 
reduction in CD271+ and Sca-1+ MSCs was reversed when compared with diabetic mice 
with insulin treatment (p<0.05), indicating that the decrease in MSCs was directly related to 
diabetic status. When examined by immunofluorescence, 21% of the total cell number were 
CD271+ in normoglycaemic mice and 13% were CD271+ in new bone in diabetic mice 
(p<0.05) (Fig. 1g). Similar results were obtained when MSCs were examined as total 
CD271+ cells per mm2 (Fig. 1h). Even though there was relatively little haematopoietic 
tissue, we also examined MSCs as CD271+CD45− to rule out the possibility that cells were 
of haematopoietic origin. Almost all single CD271+ cells were also CD45−, confirming that 
the CD271+ cells detected were not haematopoietic (Fig. 1i). Interestingly, leucocyte 
numbers (CD45+ cells) were 1.5-fold higher in mice with diabetes compared with 
normoglycaemic mice (p<0.05). This diabetic increase was restored to normal levels in 
diabetic mice that received insulin treatment (p<0.05) (Fig. 1j), consistent with reports that 
diabetes enhances the inflammatory response during fracture healing [12].
The diabetes-induced decrease in MSC number is due to enhanced TNFα levels
Enhanced TNFα level is a key diabetic feature that contributes to diabetes-impaired soft and 
hard tissue wound healing [7, 29, 30]. Indeed, TNFα levels were 3.2-fold higher in diabetic 
compared with normoglycaemic mice, and pegsunercept treatment restored TNFα to normal 
levels (p>0.05) (Fig. 2a). Moreover, diabetic mice had reduced bone formation and 
decreased numbers of osteoblasts, which were restored to normal levels by TNFα inhibition 
(p<0.05) (Fig. 2b-d). The CD271+ MSC number decreased by almost 40% in diabetic mice 
(p<0.05), and TNFα inhibition blocked the loss of MSCs caused by diabetes (p<0.05) (Fig. 
2e). Sca-1+ cells were also reduced by 50% in a TNFα-dependent manner in diabetic mice 
(Fig. 2f). These cells were not of haematopoietic origin as almost all Sca-1+ cells were 
CD45− (Fig. 2g). Moreover, pegsunercept treatment in diabetic mice decreased CD45+ cells 
to normoglycaemic levels (p<0.05) (Fig. 2h). Thus, TNFα is largely responsible for the 
decrease in MSC number in diabetic fracture healing.
Diabetes increases apoptosis and decreases proliferation in MSCs
To identify potential mechanisms to explain the reduction in MSCs in fracture healing, we 
examined MSC apoptosis and proliferation. The number of TUNEL+ cells increased by 2.2-
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fold in diabetic fracture calluses compared with those in normoglycaemic mice (p<0.05) 
(Fig. 3a). The number of apoptotic MSCs (double CD271+TUNEL+ cells) increased 
significantly, by 3.1-fold, in diabetic mice and insulin treatment blocked the MSC apoptosis 
(p<0.05) (Fig. 3b). Immunofluorescence with a Ki67-specific antibody was used to detect 
actively proliferating cells. Diabetes reduced the number of Ki67+ cells by 54% (p<0.05), 
and insulin treatment largely restored this (p<0.05), so that it was similar to 
normoglycaemic levels (Fig. 3c). Diabetes reduced the number of proliferating MSCs 
(CD271+Ki67+) by 33% (p<0.05), and insulin treatment in diabetic mice restored MSC 
proliferation (p<0.05) similar to normal levels (Fig. 3d).
TNFα inhibition directly rescues diabetic effects in MSC apoptosis and proliferation
To determine how TNFα affects MSC apoptosis and proliferation, double 
immunofluorescence was performed on femoral fracture specimens treated with or without 
pegsunercept. Diabetic mice had a 3.6-fold increase in the total number of apoptotic cells 
compared with normoglycaemic mice (p<0.05); this was reduced to normal values with 
pegsunercept treatment (p<0.05) (Fig. 4a). Diabetic mice had a 3.9-fold increase in MSC 
apoptosis (p<0.05), which was reversed with pegsunercept treatment (p<0.05) (Fig. 4b). 
Approximately 13% of all cells in the new bone were proliferating as measured by Ki67 
(Fig. 4c). In diabetic fractures, this number was lower at approximately 8%, and reverted to 
normal levels with pegsunercept treatment (p<0.05) (Fig. 4c). When MSCs were examined, 
approximately 33% were proliferating; diabetes decreased this to about 21% (p<0.05) (Fig. 
4d). The reduction in MSC proliferation caused by diabetes was rescued by pegsunercept 
treatment (p<0.05) (Fig. 4d). Taken together, our data suggest that elevated TNFα levels in 
diabetic fracture calluses induced higher levels of MSC apoptosis and reduced MSC 
proliferation.
TNFα directly induces apoptosis and reduces proliferation in mouse MSCs and hBMSCs in 
vitro
To investigate whether TNFα alone is sufficient to induce diabetes-like effects in MSCs, in 
vitro experiments were carried out using the mouse MSC (mMSC) line, C3H10T1/2. 
Annexin V was used to detect apoptotic cells with membrane disruption. Annexin V+ 
mMSCs increased by 1.6-fold after 24 h of TNFα treatment (p>0.05), and to 2.9-fold after 
72 h (p<0.05) (Fig. 5a). Similarly, TNFα increased cleaved caspase-3+ mMSCs, a 
downstream initiator of apoptosis, by 3.7-fold (p<0.05) (Fig. 5b). Moreover, TNFα 
treatment decreased the mMSC proliferation rate after 24 h and 72 h by 36% and 73%, 
respectively (p<0.05) (Fig. 5c). Primary hBMSCs were also examined. TNFα stimulated 
apoptosis in hBMSC, reflected by a 2.8-fold increase in annexin V+ cells and a 2.4-fold 
increase in cleaved caspase 3+ cells (p<0.05) (Fig. 5d, e). The proliferation of hBMSCs 
decreased by 69% with TNFα stimulation (p<0.05) (Fig. 5f). Thus, TNFα directly 
stimulates apoptosis and reduces proliferation in both mMSCs and hBMSCs, similar to the 
effect of diabetes shown in vivo.
Ko et al. Page 6
Diabetologia. Author manuscript; available in PMC 2016 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Diabetes enhances forkhead box protein O1 nuclear localisation in MSCs in a TNFα-
dependent manner
Forkhead box protein O1 (FOXO1), a transcription factor induced by TNFα, is implicated in 
the regulation of apoptosis and proliferation [31]. The percentage of all nucleated cells with 
FOXO1 localised to the nucleus increased by 5.8-fold in fractures in diabetic compared with 
normoglycaemic mice (p<0.05) (Fig. 6a). TNFα inhibition significantly reduced FOXO1+ 
nuclear localisation (p<0.05) (Fig. 6a). In contrast, diabetes had little effect on the overall 
level of FOXO1, as approximately 30% of nucleated cells were FOXO1+ in 
normoglycaemic and diabetic fracture calluses (p>0.05) (Fig. 6b). When Sca-1+ MSCs were 
examined, more than 90% of Sca-1+ cells were FOXO1+, with little difference detected 
between groups (Fig. 6c). However, diabetes greatly increased the nuclear localisation of 
FOXO1+ in Sca- 1+ MSC, and this was significantly reduced with TNFα inhibition (p<0.05) 
(Fig. 6d). These data suggest that diabetes-induced TNFα stimulates nuclear localisation of 
FOXO1 in MSCs but does not affect its production.
FOXO1 knockdown prevents TNFα-mediated MSC apoptosis and anti-proliferation
To establish that TNFα directly induces FOXO1 activity in MSCs, in vitro assays were 
carried out in hBMSCs following the approach described above. TNFα stimulated FOXO1 
nuclear localisation after 24 h but did not alter overall FOXO1 levels (Fig. 7a, b). The effect 
of TNFα was examined in hBMSCs with FOXO1 knockdown. Specific siRNA reduced 
FOXO1 mRNA levels by approximately 80% and protein levels by 60% (Fig. 7c, d). TNFα-
stimulated annexin V+ hBMSCs were reduced by 43%, and cleaved caspase 3+ hBMSCs 
were reduced by 33% with FOXO1 knockdown (p<0.05) (Fig. 7e, f). Moreover, TNFα 
reduced serum-stimulated hBMSC proliferation by 45%, and FOXO1 silencing restored this 
inhibition by 90% of the decrease (p<0.05) (Fig. 7g).
TNFα upregulates FOXO1-dependent apoptotic and cell cycle arrest genes in hBMSCs
To understand the molecular mechanism by which FOXO1 affects MSCs under 
inflammatory conditions, genes that regulate apoptosis and cell cycle were evaluated further. 
Among the apoptotic genes examined (BIM [also known as BCL2L11], Fas ligand [FASLG], 
caspase-3 [CASP3], caspase-8 [CASP8] and caspase-9 [CASP9]), caspase-8 and caspase-9 
were significantly upregulated by TNFα. For both, silencing FOXO1 restored the mRNA 
levels to a normal value (Fig. 8a, b). When genes that regulate proliferation were examined 
(CDK1, cyclin D [CCND1], P21 [also known as CDKN1A] and P27 [also known as 
CDKN1B]), P21 and P27 mRNA levels were upregulated by TNFα, with the effect on both 
mRNAs blocked by FOXO1 knockdown (Fig. 8c, d).
Discussion
A better understanding of how diabetes impairs fracture healing is important. Diabetes is an 
increasingly important healthcare issue and the disease has a significant impact on the 
skeleton and interferes with fracture repair [32, 33]. Here, we report the deleterious effects 
of diabetes on MSC viability during fracture healing. Diabetes reduced the number of 
endogenous MSCs in areas of endochondral bone formation, with the number restored to 
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normal values by insulin treatment. To better understand mechanistically how diabetes 
affects MSCs, diabetic animals were treated with the TNFα inhibitor, pegsunercept.
Pegsunercept significantly increased the MSC number, demonstrating that diabetes-
enhanced inflammation played a major role in reducing the MSC number. Furthermore, 
diabetes significantly increased MSC apoptosis and reduced proliferation in vivo. These 
negative effects were mediated by diabetes-enhanced inflammation. In vitro experiments 
demonstrated that TNFα directly increased MSC apoptosis and reduced DNA synthesis. The 
effect of TNFα was dependent on FOXO1 activity.
To quantify MSCs in vivo, specific markers were used, CD271 and Sca-1, which accurately 
identify MSC in areas with little haematopoietic tissue [29, 36, 36]. Moreover, virtually all 
CD271+ and Sca-1+ cells were CD45−CD271+ cells found in dermal and adipose tissue 
exhibit robust tri-lineage mesenchymal potential [34]. In addition, CD271+ cells 
administered in vivo home to fracture sites in mice [35]. Furthermore, Sca-1 is found on 
MSCs in murine synovial membrane and skeletal muscle that exhibits mesengenic properties 
[36, 37]. STZ-induced diabetes drastically reduced the number of MSCs in areas of new 
bone. Insulin treatment reversed serum glucose to normal levels in STZ-treated mice. It also 
restored the number of MSCs to normal levels in STZ-diabetic mice, together with the 
amount of new bone and osteoblast numbers. Thus, the reduction is not an untoward effect 
of STZ-induced diabetes in this model. Previous studies have demonstrated that bone 
marrow samples derived from diabetic mice have fewer MSCs compared with 
normoglycaemic animals [38, 39], and have significantly decreased MSC-colony-forming 
units ex vivo [40]. Our studies demonstrate for the first time that diabetic animals exhibit 
lower numbers of local endogenous MSCs in fracture callus, a mesenchymal tissue, in 
accordance with decreased bone formation in diabetic fracture healing. Here, we have 
identified TNFα-mediated MSC apoptosis and anti-proliferation as the two mechanisms that 
explain the reduced MSC numbers in diabetic fracture healing. MSC apoptosis was returned 
to normal values when TNFα was inhibited in vivo, and TNFα sufficiently induced 
caspase-3 activation and apoptosis in hBMSCs in vitro. Previous in vitro studies have 
demonstrated that high glucose levels stimulate apoptosis and induce senescence in adipose-
derived MSCs [41]. Consistent with these findings, a recent study showed that TNFα 
induced apoptosis in rat MSCs in vitro [42].
An essential component of an adequate healing process is the proliferative capacity of 
regenerative cells. MSC proliferation was reduced by 33% in diabetic fracture calluses, and 
TNFα inhibition significantly restored MSC proliferation. Moreover, TNFα induced 
upregulation of genes that interfere with progression through the cell cycle in a FOXO1-
dependent manner. No previous in vivo studies have identified this mechanism for the effect 
of diabetes on MSC proliferation during fracture healing. Increased TNFα levels may delay 
the healing process in other mesenchymal tissues affected by diabetes.
FOXO1 is a transcription factor that regulates apoptosis and proliferation, and it is subject to 
activation by diabetic inflammatory stimuli in fibroblasts [29]. Diabetes increased FOXO1 
nuclear localisation in MSCs in diabetic fracture approximately sixfold, and TNF inhibition 
significantly reduced this increase. FOXO1 knockdown in hBMSCs prevented the negative 
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impact of TNFα on MSC apoptosis and proliferation. This is consistent with previous 
reports that FOXO1 plays an adverse role in fibroblasts [29], microvascular cells [43] and 
chondrocytes [7] in diabetic conditions. Thus, a high level of FOXO1 activation may 
mediate some of the negative effects of diabetes and contribute to diabetic complications.
Treatment of diabetic fractures with MSCs can promote healing [44]. Our studies suggest an 
alternative approach, which would be to enhance survival and support the proliferation of 
endogenous MSCs by reducing prolonged inflammation in diabetic fracture healing. This 
may be a simpler and more pragmatic approach than treatment of diabetic fractures with 
MSCs. Thus, targeting endogenous MSCs in order to maximise their regenerative potential 
using pharmacological intervention may ultimately be safer and more cost effective.
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Fig. 1. 
Diabetes decreases the number of MSCs in areas of endochondral bone formation in healing 
fractures. (a) Left, H&E-stained section of a mouse tibial fracture callus on day 16 (original 
magnification ×40). Right, area of new endochondral bone formation (original magnification 
×200). The dashed line demarcates the border between new bone and cartilage. (b)The area 
of new bone was quantified from H&E-stained sections of normoglycaemic mice, diabetic 
and diabetic + insulin-treated mice. (c) Bone formation normalised to total callus area 
among different groups. (d) Osteoblast counts were expressed as the number per mm of 
bone length in Toluidine Blue-stained sections. (e, f) CD271+ and Sca-1+ cells were 
quantified using an index ranging from 0 to 4 as described in Methods. (g–j) Images were 
analysed by immunofluorescence in normoglycaemic, diabetic and diabetic + insulin mice 
on day 16 after fracture. (g) CD271+ cells per total cell number determined by DAPI 
staining; (h) CD271+ cells per mm2; (i) CD271+CD45− cells per total cell number; (j) 
CD45+ cells per total cell number. n=5 each. *p<0.05 vs normoglycaemic or diabetic + 
insulin-treated mice. Diab, diabetic; Ins, insulin; NG, normoglycaemic; Ob, osteoblasts
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Fig. 2. 
Inhibition of TNFα reduces the loss of MSC in diabetic but not normoglycaemic mice 
during fracture healing. Paraffin sections of 16 day femoral fracture calluses from the 
normoglycaemic mice, diabetic mice, normoglycaemic + pegsunercept and diabetic + 
pegsunercept were stained and analysed. (a) TNFα was measured as the mean fluorescent 
intensity in areas of newly formed bone in the fracture callus. (b) Bone area measured from 
the H&E-stained sections. (c) Bone formation normalised to total callus area in different 
groups. (d)Osteoblast counts were expressed as the number per mm bone. (e–h) 
Immunofluorescence analysis was carried out with CD271-, Sca-1- and CD45-specific 
antibodies. (e) CD271+ cells per total cell number; (f) Sca-1+ cells per total cell number; (g) 
Sca-1+CD45− cells per total cell number; (h) CD45+ cells per total cell number. n=6 each. 
*p<0.05 vs all groups. Diab, diabetic; NG, normoglycaemic; Ob, osteoblasts; PEG, 
pegsunercept
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Fig. 3. 
Diabetes increases apoptosis and decreases proliferation of MSCs in vivo. Fractures from 16 
day specimens of normoglycaemic, diabetic and diabetic + insulin groups were examined for 
apoptotic and proliferating cells. Apoptotic cells were simultaneously identified with a 
fluorescent TUNEL assay or proliferating cells were identified by immunofluorescence with 
Ki67 antibody. Single- or double-positive cells were examined by multi-colour fluorescent 
microscopy. (a) TUNEL+ cells per total cell number; (b) CD271+TUNEL+ cells per total 
CD271+ cells; (c) Ki67+ cells per total cell number; (d) CD271+Ki67+ cells per total 
CD271+ cells. n=5 each. *p<0.05 vs normoglycaemic or diabetic + insulin. Diab, diabetic; 
Ins, insulin; NG, normoglycaemic
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Fig. 4. 
Inhibition of TNFα rescues diabetes-induced apoptosis and anti-proliferation in MSCs. 
Femoral calluses 16 days after fracture in normoglycaemic and diabetic mouse groups 
treated with or without PEG were double-stained with CD271 antibody and apoptotic 
marker (TUNEL) or proliferation marker (Ki67). (a) TUNEL+ cells per total cell number; 
(b) CD271+TUNEL+ cells per total CD271+ cells; (c) Ki67+ cells per total cell number; (d) 
CD271+Ki67+ cells per total CD271+ cells. n=6 each. *p<0.05 vs normoglycaemic and 
diabetic + pegsunercept; †p<0.05 vs normoglycaemic. Diab, diabetic; NG, normoglycaemic; 
PEG, pegsunercept
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Fig. 5. 
TNFα induces apoptosis and reduces proliferation in mMSCs and hBMSCs. C3H10T1/2 
cells (mMSC) and hBMSCs were treated with TNFα (10 ng/ml) for 24–72 h. Apoptosis was 
detected using annexin V and cleaved caspase-3 antibody, and proliferation was measured 
by the BrdU assay. (a, d) Annexin V+ cells per total cell number in mMSCs and hBMSCs, 
respectively. (b, e) Cleaved caspase-3+ cells per total cell number after 72 h of TNFα 
treatment in mMSCs and hBMSCs, respectively. (c, f) BrdU levels after serum-stimulated 
proliferation, measured at absorbance = 450 nm. *p<0.05 vs 0 h treatment
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Fig. 6. 
TNFα inhibition reduces FOXO1 nuclear localisation in diabetic fractures in vivo. 
Immunofluorescence was carried out in femoral calluses 16 days after fracture in NG and 
diabetic mouse groups treated with or without PEG using Sca-1 and/or FOXO1 antibody. 
FOXO1+ and Sca-1+FOXO1+ cell numbers were examined. Nuclear localisation of FOXO1 
was determined by the co-localisation of FOXO1 and DAPI stain. (a) Nuclear FOXO1+ 
cells per total cell number; (b) total FOXO1+ (cytoplasm or nucleus) per total cell number; 
(c) FOXO1+ cells per total Sca-1+ cells; (d) the ratio of Sca-1+nuclear FOXO1+ cells to 
Sca-1+total FOXO1+ cells.n=6 each. *p<0.05 vs all groups. Diab, diabetic; NG, 
normoglycaemic; PEG, pegsunercept
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Fig. 7. 
Silencing FOXO1 interferes with TNFα-mediated apoptosis and anti-proliferation. The 
hBMSCs were incubated in TNFα for 72 h, and immunofluorescence was carried out with 
FOXO1 antibody. For some experiments, hBMSCs were transfected with scrambled siRNA 
or FOXO1 siRNA (siFOXO1) for 6 h prior to TNFα incubation. (a) nuclear FOXO1+ cells 
per total cell number; (b) FOXO1 levels measured by mean fluorescent intensity per cell. (c, 
d) relative FOXO1 mRNA levels (c) and FOXO1 protein levels (d) after siFOXO1 
silencing. (e) Annexin V+ cells per total cell number; (f) cleaved caspase-3+ cell per total 
cell number; (g) BrdU levels after serum-stimulated proliferation. *p<0.05 vs control 
counterpart; †p<0.05 vs siRNA controls. mfi, mean fluorescent intensity; siScr, scrambled 
siRNA
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Fig. 8. 
TNFα-mediated apoptosis and cell cycle gene regulation is FOXO1 dependent. hBMSCs 
were transfected with control (scrambled siRNA) or FOXO1 siRNA, followed by TNFα 
treatment for 72 h. Quantitative RT-PCR was carried out and ribosomal protein L32 mRNA 
was used to normalise the mRNA values. (a–d) Quantification of relative mRNA fold 
changes for: (a) CASP8; (b) CASP9; (c) P21; and (d) P27. *p<0.05 vs all groups
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